Autoantibodies to Tumor-Associated Antigens in Breast Carcinoma
Author Information
Author(s): Piura Ettie, Piura Benjamin
Primary Institution: Sapir Medical Center, Sackler School of Medicine, University of Tel-Aviv
Hypothesis
Can autoantibodies to tailor-made panels of tumor-associated antigens improve the diagnosis of breast carcinoma?
Conclusion
Using autoantibody assays to panels of tumor-associated antigens can enhance the sensitivity and specificity for diagnosing breast carcinoma compared to single antigen assays.
Supporting Evidence
- Autoantibodies to tumor-associated antigens can be detected even before clinical symptoms appear.
- Using a panel of tumor-associated antigens improves diagnostic sensitivity compared to single antigen tests.
- Detection of autoantibodies can occur up to four years before traditional imaging methods like mammography.
Takeaway
Doctors can find special proteins in the blood of women with breast cancer that help catch the disease earlier than regular tests.
Methodology
The study used enzyme-linked immunosorbent assay (ELISA) to detect autoantibodies in the sera of breast carcinoma patients and controls.
Limitations
The study is still investigational and should be used alongside traditional diagnostic methods.
Participant Demographics
The study included 97 breast carcinoma patients, 40 ductal carcinoma in situ patients, and 94 normal controls.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website